We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+10.58%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$604M
AUM Growth
-$93M
(-13%)
Cap. Flow
-$139M
Cap. Flow
% of AUM
-22.99%
Top 10 Holdings %
Top 10 Hldgs %
48.64%
Holding
92
New
16
Increased
10
Reduced
22
Closed
33
Avg Time Held Equity + Options
3
quarters
Top 10 Avg Time Held Equity + Options
1.2
quarters
Top 20 Avg Time Held Equity + Options
1.4
quarters
Avg Time Held Equity only
3.1
quarters
Top 10 Avg Time Held Equity only
1.2
quarters
Top 20 Avg Time Held Equity only
1.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Allogene Therapeutics
ALLO
|
+$29.3M |
| 2 |
Globus Medical
GMED
|
+$25.7M |
| 3 |
Cencora
COR
|
+$21M |
| 4 |
Cigna
CI
|
+$16.3M |
| 5 |
Viatris
VTRS
|
+$14.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Icon
ICLR
|
+$27.8M |
| 2 |
Corcept Therapeutics
CORT
|
+$27.2M |
| 3 |
Dianthus Therapeutics
DNTH
|
+$27.1M |
| 4 |
LivaNova
LIVN
|
+$26.8M |
| 5 |
Embecta
EMBC
|
+$16.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.2% |
| 2 | Industrials | 6.36% |
| 3 | Miscellaneous | 3.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
BridgeBio Oncology
BBOT
$251M
| $995K | 0.16% |
130,628
| – | – |
2025 Q3
3 quarters
|
|
52
TELA Bio
TELA
$46.9M
| $477K | 0.08% |
636,300
| – | – |
2024 Q4
6 quarters
|
|
53
Adagio Medical Holdings
ADGM
$3.45M
| $455K | 0.08% |
698,989
-589,472
| -46% | -$576K |
2025 Q4
2 quarters
|
|
54
NeuroOne Medical Technologies
NMTC
$9.93M
| $252K | 0.04% |
82,767
-2
| -0% | -$8 |
2025 Q2
4 quarters
|
|
55
Enveric Biosciences
ENVB
$6.58M
| $248K | 0.04% |
+180,000
| New | +$432K |
2026 Q2
0 quarters
|
|
56
Modular Medical
MODD
$19.6M
| $118K | 0.02% |
26,190
| – | – |
2022 Q2
16 quarters
|
|
57
QT Imaging Holdings
QTI
$38.3M
| $62K | 0.01% |
+15,236
| New | +$84.7K |
2026 Q2
0 quarters
|
|
58
DELISTED
Rocket Pharmaceuticals Warrant
RCKTW
| $1.48K | ﹤0.01% |
400,000
| – | – |
2023 Q1
13 quarters
|
|
59
DELISTED
Humacyte Inc Warrant
HUMAW
| $477 | ﹤0.01% |
49,998
| – | – |
2023 Q1
13 quarters
|
|
60
Abivax
ABVX
$7.42B
| – | – |
-135,800
| Closed | -$15.1M | – |
|
61
Biohaven
BHVN
$1.73B
| – | – |
-1,163,926
| Closed | -$9.85M | – |
|
62
BioMarin Pharmaceuticals
BMRN
$10.7B
| – | – |
-194,226
| Closed | -$11M | – |
|
63
Compass Pathways
CMPS
$1.56B
| – | – |
-1,506,525
| Closed | -$8.33M | – |
|
64
PUT
Centene
CNC
$33.1B
| – | – |
-100,000
| Closed | -$3.27M | – |
|
65
Context Therapeutics
CNTX
$26.3M
| – | – |
-917,922
| Closed | -$2.4M | – |
|
|
66
Corcept Therapeutics
CORT
$12.9B
| – | – |
-674,759
| Closed | -$27.2M | – |
|
67
DELISTED
Crinetics Pharmaceuticals
CRNX
| – | – |
-249,887
| Closed | -$9.08M | – |
|
68
PUT
Elicio Therapeutics
ELTX
$47.6M
| – | – |
-11,700
| Closed | -$125K | – |
|
|
69
Embecta
EMBC
$338M
| – | – |
-1,847,850
| Closed | -$16.3M | – |
|
70
Enanta Pharmaceuticals
ENTA
$349M
| – | – |
-40,000
| Closed | -$505K | – |
|
71
Erasca
ERAS
$5.28B
| – | – |
-5,000
| Closed | -$80.9K | – |
|
72
Edgewise Therapeutics
EWTX
$4.14B
| – | – |
-268,986
| Closed | -$8.47M | – |
|
73
Foghorn Therapeutics
FHTX
$113M
| – | – |
-122,889
| Closed | -$587K | – |
|
74
Structure Therapeutics
GPCR
$1.67B
| – | – |
-209,093
| Closed | -$10.1M | – |
|
75
Haemonetics
HAE
$5.54B
| – | – |
-220,672
| Closed | -$12.4M | – |
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Sio Capital Management held 92 positions worth $604M, down 13% from $697M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Sio Capital Management withdrew a net $139M in Q2 2026, closing 33 positions and reducing 22 holdings. Its most notable exit was Corcept Therapeutics, an estimated $27.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier, followed by Industrials and Miscellaneous.
Against the trend, Sio Capital Management opened a new position in Allogene Therapeutics worth $27.7M.
- Sio Capital Management's largest Q2 2026 buy was Allogene Therapeutics: 13,323,431 shares worth $27.7M.
- Sio Capital Management added most to Cencora in Q2 2026, an estimated $21M increase.
- Sio Capital Management's biggest Q2 2026 reduction was Icon, cutting an estimated $27.8M.
- Sio Capital Management fully exited Corcept Therapeutics in Q2 2026, selling an estimated $27.2M.
- Sio Capital Management's ten largest holdings make up 49% of its $604M portfolio in Q2 2026.
- Sio Capital Management opened 16 new positions and closed 33 in Q2 2026.
- Sio Capital Management's portfolio value fell 13% quarter-over-quarter to $604M.
Based on Sio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.